Targed Biopharmaceuticals Raises Eur 39 Million In Series A Financing To Bring Groundbreaking Thrombolytic Treatment To Patients
Targed Biopharmaceuticals Raises Eur 39 Million In Series A Financing To Bring Groundbreaking Thrombolytic Treatment To Patients
02/22/22, 3:00 AM
Money raised
€39 million
Round Type
series a
TargED Biopharmaceuticals ("TargED"), a private biotechnology company focused on developing improved treatments for thrombotic diseases, today announces it has raised Series A financing of EUR 39 million to accelerate development of its lead compound, Microlyse. The financing was led with equal contribution by an international syndicate comprising Andera Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures, and joined by existing investors FIRST (Managed by BioGeneration Ventures), Curie Capital and Utrecht Health Seed Fund. TargED will focus development on two initial indications: acquired Thrombotic Thrombocytopenia Purpura (aTTP) and Acute Ischemic Stroke (AIS).
Company Info
Additional Info
TargED Biopharmaceuticals B.V. is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies ("VhH") to deliver enzymes to sites of thrombosis, enabling 'targeted' thrombolysis. The lead compound is Microlyse, which is currently under development for thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.
TargED, a spin-off of the University Medical Center Utrecht, was founded in July 2020 by Associate Professor at the Department of Clinical Chemistry and Haematology, Coen Maas, PhD, an expert in thrombosis and hemostasis, Steven de Maat, PhD, an expert in recombinant protein development and optimization, Marc van Moorsel, researcher with focus on Acute Ischemic Stroke and Kristof Vercruysse, with more than 20 years of experience in bringing biopharmaceutical compounds from pre-clinical proof of concept to market, most notably, Caplacizumab for Thrombotic Thrombocytopenic Purpura at Ablynx between 2007 and 2013.
For more information please visit www.targedbiopharmaceuticals.com
www.linkedin.com/company/targedbiopharmaceuticals/